Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pasireotide by Recordati for Medullary Thyroid Cancer: Likelihood of Approval
Pasireotide is under clinical development by Recordati and currently in Phase II for Medullary Thyroid Cancer. According to GlobalData, Phase...
Pasireotide by Recordati for Hypoglycemia: Likelihood of Approval
Pasireotide is under clinical development by Recordati and currently in Phase I for Hypoglycemia. According to GlobalData, Phase I drugs...
Pasireotide by Recordati for Hypoglycemia: Likelihood of Approval
Pasireotide is under clinical development by Recordati and currently in Phase II for Hypoglycemia. According to GlobalData, Phase II drugs...
Pasireotide by Recordati for Medullary Thyroid Cancer: Likelihood of Approval
Pasireotide is under clinical development by Recordati and currently in Phase II for Medullary Thyroid Cancer. According to GlobalData, Phase...